MedPath

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Terminated
Conditions
Prostate Cancer
Interventions
Biological: Sipuleucel-T
Registration Number
NCT01727154
Lead Sponsor
Dendreon
Brief Summary

The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).

Detailed Description

Subjects will receive sipuleucel-T, and potentially other medications, as part of the clinical trial in which they are concurrently enrolled. For this study, cellular and humoral immune responses will be assessed. No additional study treatments will be conducted beyond what is required for the subject's concurrent clinical trial.

Recruitment & Eligibility

Status
TERMINATED
Sex
Male
Target Recruitment
139
Inclusion Criteria
  • Subjects must be at least 18 years of age
  • Subjects with prostate cancer who are enrolled in a clinical trial of sipuleucel-T (including a Dendreon-sponsored clinical trial or registry, or an IIT)
  • Subjects have not yet undergone leukapheresis for their first dose of sipuleucel-T
  • Subjects must understand and sign an informed consent form prior to their first leukapheresis
Exclusion Criteria

•None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Sipuleucel-TSipuleucel-T-
Primary Outcome Measures
NameTimeMethod
The Percentage of Subjects Who Exhibit Any Immune Response at Any Post-treatment Time Point (6, 10, 14, 26, 39, and 52 Weeks After the First Infusion of Sipuleucel-T).Each subjects was to be followed for approximately 52 weeks beginning with the date of the subject's first infusion of siupleucel-T.

The primary immune response analysis population will include all subjects who receive all 3 infusions of sipuleucel-T. The primary analysis will measure the percentage of subjects who exhibit any immune response at any post-treatment time point (6, 10, 14, 26, 39, and 52 weeks after the first infusion of sipuleucel-T).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (37)

Tufts Medical Center

🇺🇸

Boston, Massachusetts, United States

Chesapeake Urology Research Associates

🇺🇸

Towson, Maryland, United States

Premier Medical Group of the Hudson Valley

🇺🇸

Poughkeepsie, New York, United States

Howard University Cancer Center

🇺🇸

Washington, District of Columbia, United States

National Translational Research Group, Inc.

🇺🇸

East Setauket, New York, United States

Oregon Urology Institute

🇺🇸

Springfield, Oregon, United States

Southeast Nebraska Hematology & Oncology Consultants, P.C. d/b/a Southeast Nebraska Cancer Center

🇺🇸

Lincoln, Nebraska, United States

Carolina Urologic Research Center

🇺🇸

Myrtle Beach, South Carolina, United States

Associated Medical Professionals of NY, PLLC

🇺🇸

Syracuse, New York, United States

21st Century Oncology

🇺🇸

Scottsdale, Arizona, United States

Prostate Oncology Specialists, Inc.

🇺🇸

Marina Del Rey, California, United States

Cancer Center of Kansas

🇺🇸

Wichita, Kansas, United States

Tower Urology / Tower Research Institute

🇺🇸

Los Angeles, California, United States

Tulane University

🇺🇸

New Orleans, Louisiana, United States

Highland Clinic

🇺🇸

Shreveport, Louisiana, United States

First Urology, PSC

🇺🇸

Jeffersonville, Indiana, United States

Michigan Institute of Urology

🇺🇸

Troy, Michigan, United States

St. Louis Cancer Care, LLP

🇺🇸

Saint Louis, Missouri, United States

Carolina Urology Partners

🇺🇸

Gastonia, North Carolina, United States

Delaware Valley Urology, LLC

🇺🇸

Mount Laurel, New Jersey, United States

Raleigh Hematology Oncology Associates, D.B.A., Cancer Centers of North Carolina

🇺🇸

Raleigh, North Carolina, United States

South Carolina Oncology Associates

🇺🇸

Columbia, South Carolina, United States

Northwest Cancer Specialists, PC

🇺🇸

Tualatin, Oregon, United States

Urology of Virginia, PLLC

🇺🇸

Virginia Beach, Virginia, United States

University of Washington Medical Centerl

🇺🇸

Seattle, Washington, United States

Urologic Specialists of Oklahoma

🇺🇸

Tulsa, Oklahoma, United States

Urologic Consultants of SE PA

🇺🇸

Bala-Cynwyd, Pennsylvania, United States

Seattle Cancer Care Alliance

🇺🇸

Seattle, Washington, United States

Texas Oncology - Fort Worth

🇺🇸

Fort Worth, Texas, United States

Northwest Cancer Specialists

🇺🇸

Vancouver, Washington, United States

The Urology Center of Colorado

🇺🇸

Denver, Colorado, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Providence Health & Services

🇺🇸

Portland, Oregon, United States

TriState Urologic Services PSC Inc., dba The Urology Group

🇺🇸

Cincinnati, Ohio, United States

Comprehensive Cancer Centers of Nevada

🇺🇸

Las Vegas, Nevada, United States

Urology Associates, P.C.

🇺🇸

Nashville, Tennessee, United States

Montefiore Medical Center

🇺🇸

Bronx, New York, United States

© Copyright 2025. All Rights Reserved by MedPath